- Home
- SG vs ETNB Comparison
SG vs ETNB Comparison
Compare SG & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SG
- ETNB
- Stock Information
- Founded
- SG 2007
- ETNB 2018
- Country
- SG United States
- ETNB United States
- Employees
- SG N/A
- ETNB N/A
- Industry
- SG Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- SG Consumer Discretionary
- ETNB Health Care
- Exchange
- SG Nasdaq
- ETNB Nasdaq
- Market Cap
- SG 1.7B
- ETNB 1.5B
- IPO Year
- SG 2021
- ETNB 2019
- Fundamental
- Price
- SG $12.27
- ETNB $10.08
- Analyst Decision
- SG Buy
- ETNB Strong Buy
- Analyst Count
- SG 13
- ETNB 8
- Target Price
- SG $26.33
- ETNB $26.43
- AVG Volume (30 Days)
- SG 4.7M
- ETNB 2.2M
- Earning Date
- SG 08-07-2025
- ETNB 08-04-2025
- Dividend Yield
- SG N/A
- ETNB N/A
- EPS Growth
- SG N/A
- ETNB N/A
- EPS
- SG N/A
- ETNB N/A
- Revenue
- SG $685,280,000.00
- ETNB N/A
- Revenue This Year
- SG $13.96
- ETNB N/A
- Revenue Next Year
- SG $19.96
- ETNB N/A
- P/E Ratio
- SG N/A
- ETNB N/A
- Revenue Growth
- SG 11.10
- ETNB N/A
- 52 Week Low
- SG $11.86
- ETNB $4.16
- 52 Week High
- SG $45.12
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- SG 33.78
- ETNB 57.88
- Support Level
- SG $13.49
- ETNB $9.66
- Resistance Level
- SG $13.39
- ETNB $10.58
- Average True Range (ATR)
- SG 0.84
- ETNB 0.55
- MACD
- SG 0.07
- ETNB -0.09
- Stochastic Oscillator
- SG 12.50
- ETNB 58.39
About SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).